Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during t...

Descripción completa

Detalles Bibliográficos
Autores principales: Inubushi, Masayuki, Miura, Hiroyuki, Kuji, Ichiei, Ito, Kimiteru, Minamimoto, Ryogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Invited Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680309/
https://www.ncbi.nlm.nih.gov/pubmed/33175360
http://dx.doi.org/10.1007/s12149-020-01549-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680309/
https://www.ncbi.nlm.nih.gov/pubmed/33175360
http://dx.doi.org/10.1007/s12149-020-01549-5

Ejemplares similares